Trends in the Quality of Evidence Supporting FDA Drug Approvals: Results from a Literature Review
Open Access
- 14 July 2022
- journal article
- review article
- Published by Duke University Press in Journal of Health Politics, Policy and Law
- Vol. 47 (6) , 649-672
Abstract
Context: New drug approvals in the US must be supported by substantial evidence from “adequate and well-controlled” trials. The Food and Drug Administration (FDA) has flexibility in how it applies this standard. Methods: We conducted a systematic literature review of PubMed for studies between 2005-2020 evaluating the design and outcomes of the key trials supporting new drug approvals in the US. We extracted data on the trial characteristics, endpoint types, and expedited regulatory pathways. Findings: Among 48 publications eligible for inclusion, 30 covered trial characteristics, 23 covered surrogate measures, and 30 covered regulatory pathways. Trends point towards less frequent randomization, double-blinding, and active controls, with variation by drug type and indication. Surrogate measures are becoming more common but are not consistently well-correlated with clinical outcomes. Drugs approved through expedited regulatory pathways often have less rigorous trial design characteristics. Conclusions: The characteristics of trials used to approve new drugs have evolved over the past two decades, along with greater use of expedited regulatory pathways and changes in the nature of drugs being evaluated. While flexibility in regulatory standards is important, policy changes can emphasize high quality data collection before or after FDA approval.Keywords
This publication has 58 references indexed in Scilit:
- Development Times, Clinical Testing, Postmarket Follow-up, and Safety Risks for the New Drugs Approved by the US Food and Drug AdministrationJAMA Internal Medicine, 2014
- Oncology Drug Development and Approval of Systemic Anticancer Therapy by the U.S. Food and Drug AdministrationThe Oncologist, 2012
- Rare Cancer Trial Design: Lessons from FDA ApprovalsClinical Cancer Research, 2012
- Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for CancerJAMA, 2011
- Accelerated Approval of Oncology Products: The Food and Drug Administration ExperienceJNCI: Journal of the National Cancer Institute, 2011
- Characteristics of orphan drug applications that fail to achieve marketing approval in the USADrug Discovery Today, 2011
- Review of Oncology and Hematology Drug Product Approvals at the US Food and Drug Administration Between July 2005 and December 2007JNCI: Journal of the National Cancer Institute, 2010
- Pivotal studies of orphan drugs approved for neurological diseasesAnnals of Neurology, 2009
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- The ethics of randomized clinical trialsThe American Journal of Medicine, 1987